Novelion Therapeutics Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2018
Novelion Therapeutics Inc. announced unaudited consolidated earnings results for the first quarter ended March 31, 2018. For the quarter, the company reported net revenue of $27,484,000 compared to $29,984,000 a year ago. Loss from operations was $21,476,000 compared to $21,663,000 a year ago. Loss before provision for income taxes was $32,669,000 compared to $30,823,000 a year ago. Net loss was $32,828,000 compared to $30,962,000 a year ago. Net loss per common share—basic and diluted was $1.76 compared to $1.67 a year ago. Non-GAAP net loss was $13,534,000 compared to $8,687,000 a year ago. Non-GAAP net loss per common share – basic and diluted was $0.72 compared to $0.47 a year ago.